TRVX.OL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 mai 2023 @ 16:09):

Stats
Dagens volum	570 454
Gjennomsnittsvolum	865 124
Markedsverdi	123.47M
EPS	NOK0 ( 2024-02-15 )
Neste inntjeningsdato	( NOK0 ) 2024-05-09
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.294
ATR14	NOK0.0540 (9.94%)

Volum Korrelasjon

Lang: 0.05 (neutral)

Kort: -0.83 (strong negative)

Signal:(37.845) Neutral

Targovax ASA Korrelasjon

10 Mest positive korrelasjoner
ANDF.OL	0.969
EFUEL.OL	0.967
KMCP.OL	0.961
KOMPL.OL	0.957
ELIMP.OL	0.953
PLT.OL	0.948
NRC.OL	0.946
NOD.OL	0.943
VOW.OL	0.942
NEL.OL	0.941

10 Mest negative korrelasjoner
EIOF.OL	-0.95
BORR.OL	-0.945
HAFNI.OL	-0.933
WWI.OL	-0.926
VAR.OL	-0.912
SNI.OL	-0.905
NKR.OL	-0.905
FROY.OL	-0.905
KAHOT.OL	-0.899
EQNR.OL	-0.898

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Targovax ASA Korrelasjon - Valuta/Råvare

-0.86
( strong negative )

-0.79
( moderate negative )

0.00
( neutral )

-0.79
( moderate negative )

-0.27
( neutral )

0.55
( weak )

Targovax ASA Økonomi

Annual	2022
Omsetning:	NOK10.00M
Bruttogevinst:	NOK10.00M (100.00 %)
EPS:	NOK-2.30

FY	2022
Omsetning:	NOK10.00M
Bruttogevinst:	NOK10.00M (100.00 %)
EPS:	NOK-2.30

FY	2021
Omsetning:	NOK0.00
Bruttogevinst:	NOK0.00 (0.00 %)
EPS:	NOK-1.271

FY	2020
Omsetning:	NOK0.00
Bruttogevinst:	NOK0.00 (0.00 %)
EPS:	NOK-1.145

Financial Reports:

No articles found.

Targovax ASA

Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.